Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 3/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679804 | 1.00 | NPC1 (0.51) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL21812065 | 0.89 | SYK (0.51) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL3781627 | 0.86 | NPC1 (0.49) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL4422428 | 0.83 | IRAK4 (0.49) | NPC1RAB9ATDP1SYKIRAK4 | |
| SCHEMBL4422426 | 0.83 | IRAK4 (0.49) | NPC1RAB9ATDP1SYKIRAK4 | |
| SCHEMBL3780111 | 0.82 | FFAR1 (0.49) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL12890444 | 0.82 | IRAK4 (0.53) | SYKIRAK4 | |
| SCHEMBL16131168 | 0.81 | NPC1 (0.46) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL3785463 | 0.80 | NPC1 (0.48) | NPC1RAB9AKDM4EHKDC1TDP1 | |
| SCHEMBL22341606 | 0.77 | NPC1 (0.58) | NPC1RAB9AKDM4EHKDC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPO-MED INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4190345-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | Epo-Med Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234541-A | Treatment of diseases by EpoR antagonists | EPO医药株式会社 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | disclosed |
| EP-3851448-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | EPO-Med Inc. (JP) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020054813-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | エポメッド株式会社 | 2020-03-19 | — | — | WO | disclosed |
| US-6495693-B2 | TREATMENT OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | AUDIA JAMES E (US) | 2001-09-06 | — | — | US | disclosed |
| US-6096782-A | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0942923-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022493-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPOR, PRLHR, AVPR1A | NPC1 4648/4885RAB9A 2945/4885KDM4E 3954/4885 |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPOR, PROKR1, HBZ | NPC1 4106/4885RAB9A 1754/4885KDM4E 1878/4885 |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | APP, BACE1, IAPP | NPC1 112/4885RAB9A 1764/4885KDM4E 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.